Peter Freeman, MD
Ophthalmology · Reno, NVNPI 1467657510
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,025 of the $2,967 with a category attached, or 68.2%. 19 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 38.9% of the total. Reporting peaked in 2024 at $1,687 and has fallen 74.8% since, to $425 in 2025.
Across 70 payments — averaging $42.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- Genentech USA, Inc.$287
- Alcon$272
- Rxsight Inc$161
- Amgen$155
- Apellis Pharmaceuticals, Inc.$144
- plus $794 from 13 others
Across 9 payments — averaging $6666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$60K
What the payments were for
- Travel & lodging$89730%
- Food & beverage$2,02568%
- Gifts$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 10 | $1,154 |
| Genentech USA, Inc. | 11 | $287 |
| Alcon | 3 | $272 |
| Rxsight Inc | 5 | $161 |
| Amgen(2 entities) | 3 | $155 |
| Apellis Pharmaceuticals, Inc. | 2 | $144 |
| AbbVie(2 entities) | 6 | $143 |
| Tarsus Pharmaceuticals, Inc. | 4 | $129 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $128 |
| Biotissue Holdings Inc. | 7 | $124 |
| Novartis | 4 | $60 |
| Astellas Pharma US Inc | 2 | $41 |
| Harrow Eye, LLC | 1 | $38 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| Oyster Point Pharma, Inc. | 1 | $27 |
| Sight Sciences, Inc. | 1 | $25 |
| Dompe US, Inc. | 1 | $20 |
| Eyepoint US, Inc. | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista Aspire IOL$794
- TENEO$794
- STELLARIS ELITE$794
- Clareon$142
- VABYSMO$125
- Syfovre$111
- XDEMVY$108
- TEPEZZA$103
How this compares
$2,967 in reported general payments places this provider in the 60th percentile of 121 ophthalmology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 43 | $40,167 |
| RestasisCyclosporine | 37 | $28,346 |
| TyrvayaVarenicline Tartrate | 23 | $19,632 |
| Cyclosporine | 13 | $10,234 |
| MieboPerfluorohexyloctane/Pf | 14 | $9,988 |
| Prednisolone Acetate | 70 | $3,418 |
| Ketorolac Tromethamine | 128 | $1,834 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $1,540 |
| Latanoprost | 88 | $1,286 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $880 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 15 | $653 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 31 | $309 |
| Brimonidine Tartrate | 29 | $273 |
| ErythromycinErythromycin Base | 20 | $236 |
| Timolol Maleate | 17 | $213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,154 | $50,15557 claims |
| AbbVieRestasis | $143 | $28,34637 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $27 | $19,63223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 121 ophthalmology providers in Nevada.
Other ophthalmology in Reno
- Arshad KhananiReno$2M
- Steve ChangReno$75K
- Matthew MillsReno$15K
- Elena GeraymovychReno$14K
- Jamison EngleReno$6K
- Kevin GamettReno$6K
- Caleb MorrisReno$4K
- William DurantReno$4K
- Hardeep DhindsaReno$3K
- Xintong LiReno$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.